欢迎访问行业研究报告数据库

行业分类

当前位置:首页 > 报告详细信息

找到报告 1 篇 当前为第 1 页 共 1

对于有免疫活性的患有肿瘤的老鼠的淋巴系统的新型Anti-VEGF-A治疗技术的效果描述

Delineating the Effect a Novel Anti-VEGF-A Therapy has on the Lymphatic System of Immunocompetent Tumor-Bearing Mice.

作者:Dellinger, M. 作者单位:Texas Univ. Southwestern Medical Center at Dallas. 加工时间:2013-12-17 信息来源:科技报告(AD) 索取原文[17 页]
关键词:医药;治疗技术;淋巴系统;Anti-VEGF-A
摘 要:Despite intense research efforts, cancer remains the second leading cause of death in the United States. Mortality is seldom caused by primary tumors, but rather by the effect of metastases on distant organs. The lymphatic system serves as a common route of metastasis for many cancers of epithelial origin. There is growing evidence that lymphangiogenesis, the sprouting of new lymphatics from pre-existing lymphatics, facilitates the dissemination of cancer. Interestingly, vascular endothelial growth factor receptor-2 (VEGFR2) signaling has been shown to stimulate lymphangiogenesis in adult mice. However, the role VEGFR2 serves in the development of the lymphatic system has not been defined. Here we use the Cre-lox system to show that the proper development of the lymphatic vasculature requires VEGFR2 expression by lymphatic endothelium. This newly identified function of VEGFR2 further defines the molecular pathways controlling the development of the lymphatic vasculature and sheds light on how therapeutic agents targeting VEGFR2 can inhibit tumor lymphangiogenesis.
© 2016 武汉世讯达文化传播有限责任公司 版权所有 技术支持:武汉中网维优
客服中心

QQ咨询


点击这里给我发消息 客服员


电话咨询


027-87841330


微信公众号




展开客服